BOSTON--(BUSINESS WIRE)--Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch of reSET-O™ for patients with Opioid Use Disorder (OUD). reSET-O, ...
Serve You Rx teams with Pear to lead access to prescription digital therapeutics (PDTs) with proven outcomes in treating substance use disorder (SUD) and opioid use disorder (OUD) and to support ...
Over 12 weeks, using reSET-O in addition to treatment as usual lowered costs by $1,014 and added 0.003 quality-adjusted life years compared with normal treatment alone. Treatment as usual was ...
BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today ...
A recently published review of real-world claims data suggests that opioid use disorder patients prescribed Pear Therapeutics' reSET-O digital therapeutic, alongside pharmacotherapy, had fewer ...
Pear Therapeutics Inc. released nine-month, real-world data showing long-term reduction in costly health care utilization categories, including inpatient stays and emergency department visits, in ...
SelectHealth teams with Pear to provide its members with covered access to Pear’s innovative prescription digital therapeutic (PDT), reSET-O ®, for the treatment of opioid use disorder (OUD) as ...
The opioid epidemic has reached critical proportions in the United States, with more than 115 people dying from opioid overdose every day. In response to a crisis created by pharmaceuticals, some ...
BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced ...
Pear Therapeutics Inc. released nine-month, real-world data showing long-term reduction in costly health care utilization categories, including inpatient stays and emergency department visits, in ...
(RTTNews) - Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced the US commercial launch of reSET-O for patients with Opioid Use Disorder or OUD. reSET-O, cleared by the US Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results